Offering the Appropriate Patient the Opportunity for Treatment with TRK InhibitorsVideo Categories: NTRK Gene Fusions
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss who may and may not be appropriate candidates for TRK inhibitor therapy.
Ken Schaecher, MD, presents his own personal opinion on the challenges of concerns related to costs of treatment by oncologists and why they should not ignore them. Supported through funding from Incyte
In this third WCMC clinical commentary entitled, Basal Cell Carcinoma Case Studies in Hedgehog Pathway Inhibition Radiation, Joel Claveau, MD, CSPQ, FRCPC; Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD and Aleksandar Sekulic, MD, PhD discuss different case studies where patients were successfully treated by Hedgehog Pathway Inhibitors.